Enanta Pharmaceuticals (NASDAQ:ENTA) Earns “Buy” Rating from HC Wainwright

Posted by Geri Gentry on Jun 23rd, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $20.00 price target on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 49.59% from the stock’s current price.

Other research analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th. Rodman & Renshaw assumed coverage on Enanta Pharmaceuticals in a report on Thursday, March 26th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Wall Street Zen cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $20.29.

Get Our Latest Research Report on ENTA

Enanta Pharmaceuticals Price Performance

Enanta Pharmaceuticals stock opened at $13.37 on Tuesday. The company has a market cap of $388.80 million, a price-to-earnings ratio of -5.16 and a beta of 0.97. The firm has a 50-day moving average of $13.32 and a 200-day moving average of $13.65. Enanta Pharmaceuticals has a one year low of $6.43 and a one year high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last released its earnings results on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%.The business had revenue of $17.16 million for the quarter, compared to the consensus estimate of $17.03 million. As a group, sell-side analysts expect that Enanta Pharmaceuticals will post -1.79 earnings per share for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. Deutsche Bank AG lifted its holdings in Enanta Pharmaceuticals by 4.6% during the 4th quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 1,055 shares during the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of Enanta Pharmaceuticals by 8.3% in the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 1,100 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Enanta Pharmaceuticals by 8.3% in the third quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 1,383 shares during the period. Quantinno Capital Management LP raised its position in shares of Enanta Pharmaceuticals by 4.9% in the first quarter. Quantinno Capital Management LP now owns 35,122 shares of the biotechnology company’s stock valued at $444,000 after purchasing an additional 1,627 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in shares of Enanta Pharmaceuticals by 13.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock worth $197,000 after buying an additional 1,940 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.